Impact of Endothelial and Leukocyte Senescence in Circulatory Shock States
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biological samples will be done to evaluate the endothelial and leukocyte senescence..
- Who it may be relevant to
- Registry conditions: Shock, Cardiovascular Diseases, Infection. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Circulatory shocks (CS) are life-threatening, acute organ dysfunction. Advances in critical care medicine have decreased early hospital mortality, increasing the number of surviving patients. Regrettably, these survivors are at increased risk of new infections but also of cardiovascular disease. The investigators hypothesize that CS with multi-organ dysfunction is associated with premature senescence of endothelial cells and immune cells and promotes endothelial thrombogenicity and immunosenescence leading to cardiovascular disease and secondary infections. The aim of this work is therefore to evaluate the contribution of endothelial and leucocytes senescence to the occurrence of secondary events (infectious and cardiovascular) in patients with a CS. It will provide a better understanding of the pathogenesis of cardiovascular and immune diseases following a CS, likely to guide new management strategies to prevent their occurrence.
Interventions
- Biological Biological samples will be done to evaluate the endothelial and leukocyte senescence.
Noninvasive, reproducible, and sensitive methods to measure cardiac function, endothelial function, and arterial stiffness will be assess.
Primary outcome measures
- The main criterion will be the acquisition of a senescent phenotype concerning leukocytes and endothelial cells. [Time frame: 1 year]
Secondary outcome measures (1)
- Incidence of cardiovascular events and secondary infection in hospitalized patients in intensive care unit for circulatory shock states [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
- Circulatory shock
- patient with health care insurance
Exclusion criteria
- Patients' refusal to participate in clinical research
- Pregnant woman
- Breastfeeding woman
- A patient with a protective order
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
France · 1 center
- Hôpitaux Universitaires de Strasbourg - Service de Réanimation médicale du NHC — Strasbourg
Publications
- Chomel L, Vogt M, Demiselle J, Le Borgne P, Tschirhart M, Morandeau V, Merdji H, Miguet L, Helms J, Meziani F, Mauvieux L. TLRs1-10 Protein Expression in Circulating Human White Blood Cells during Bacterial and COVID-19 Infections. J Innate Immun. 2024;16(1):216-225. doi: 10.1159/000536593. Epub 2024 Mar 8. PMID 38461810
Identifiers
NCT: NCT03559569 · 7031